<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9EF988EE-B455-4063-9D7C-C49F92268316"><gtr:id>9EF988EE-B455-4063-9D7C-C49F92268316</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:surname>Birdsall</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117532193"><gtr:id>3A342773-5857-4DA4-A967-2196F1F8646D</gtr:id><gtr:title>G-protein coupled receptors and their interactions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117532193</gtr:grantReference><gtr:abstractText>In many illnesses such as Alzheimers Disease and Parkinsons Diseases, certain signalling mechanisms within the brain become too weak. This deficit can be the cause of the clinical signs and problems associated with the disease. The aim of my research is to understand these signalling mechanisms and to discover new ways in which disrupted signalling mechanisms can be normalised, thereby eliminating the symptoms and maybe helping to slow down or stop the progress of the disease. Molecules which act in this way to tune up the affected natural signalling mechanisms have been discovered and these may eventually be developed into drugs which can be used clinically to treat a number of important diseases where effective medicines are not currently available.</gtr:abstractText><gtr:technicalSummary>G protein-coupled receptors constitute one of the largest superfamilies of proteins in the human genome. Each member shares structural and/or sequence motifs and operates by common transduction mechanisms to mediate the transmission of extracellular signals into biochemical or electrophysiological responses within a cell. The signalling species is a specific endogenous molecule (e.g. neurotransmitter or hormone) that binds to the receptor. This results in activation GDP/GTP exchange at intracellularly located GTP-binding proteins and propagation of the signal. It is estimated that 30-40% of drugs in current use produce their therapeutic actions by binding to G protein-coupled receptors. They either mimic (in the case of agonists) or block (in the case of antagonists) the action of the endogenous signalling molecule by competing at the same site on a specific receptor. The effect of such drugs is to either produce a continuous stimulation or chronic blockade of receptor function at all the receptor molecules in the body, neither of which is necessarily always desirable. The research interests of this laboratory are focussed around the investigation of the mechanisms of activation of G protein-coupled receptors, the discovery of novel pharmacological mechanisms of regulating the binding and function of these receptors, and the molecular and structural basis of these phenomena. We are investigating in detail the binding and functional properties of a number of G protein-coupled receptors, including muscarinic receptors, adrenergic receptors and adenosine receptors. Existing models of agonist induced receptor-G protein coupling and activation do not explain our data: this may be due to the presence of receptor-receptor interactions which we have detected. Receptor-G protein, receptor GFP and receptor-GFP-G protein fusion constructs, modelling studies of these receptors based on the crystal structure of rhodopsin, and site-directed mutagenesis will be used to further investigate these phenomena and allow us to develop a suitable model for the activation of these receptors. We are now using total internal reflection fluorescence (TIRF) microscopy to investigate the mobility, clustering and dimerisation status of G-protein coupled receptors in living cells at the single molecule level. For a number of years we have studied allosteric sites on G-protein coupled receptors and the molecules which bind to these sites to regulate receptor function. These molecules have novel forms of selectivity and are being developed by MRC Technology to provide lead molecules in a number of therapeutic areas including the alleviation of the cognition problems in the early stages of Alzheimers Disease. We are using mutated receptors to characterise molecular structure of the two allosteric binding sites on one of these receptors, the M1 muscarinic acetylcholine receptor. All our work is carried out on cloned wild type, chimeric or mutated human receptors, expressed transiently or permanently in a variety of cell lines. Binding is measured using radioligand assays, and receptor function measured in membranes and whole cells. The TIRF studies are performed on apparatus built within the Division of Physical Biochemistry at NIMR.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1973-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>566305</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BE319A0D-5123-4081-9112-4B70B3AAF849</gtr:id><gtr:title>Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27b6f46a7c7ebe1168882451d1b18cc6"><gtr:id>27b6f46a7c7ebe1168882451d1b18cc6</gtr:id><gtr:otherNames>Lin DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>pm_15899_29_22859723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA3117F6-354D-418D-A871-AF1C4C92950D</gtr:id><gtr:title>Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8da78ca2b499558bf594fed53ad23091"><gtr:id>8da78ca2b499558bf594fed53ad23091</gtr:id><gtr:otherNames>Tr?nkle C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>191803BF9F2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>861F05B1-1C30-475A-8417-CD464A0700CC</gtr:id><gtr:title>Pharmacological characterisation of strychnine and brucine analogues at glycine and alpha7 nicotinic acetylcholine receptors.</gtr:title><gtr:parentPublicationTitle>European journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a69c7654a8c1af17b4631a0993d3662"><gtr:id>8a69c7654a8c1af17b4631a0993d3662</gtr:id><gtr:otherNames>Jensen AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2999</gtr:issn><gtr:outcomeId>25C16FB0FB3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61CAC919-E6B9-4F06-B3A5-A0E3E0EBB763</gtr:id><gtr:title>Different interactions between MT7 toxin and the human muscarinic M1 receptor in its free and N-methylscopolamine-occupied states.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84c518320fab0a9bafcee75eaa029168"><gtr:id>84c518320fab0a9bafcee75eaa029168</gtr:id><gtr:otherNames>Fruchart-Gaillard C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>B23BB170D52</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B21B6DF-810C-4FE5-9F27-AE3559B2AEC2</gtr:id><gtr:title>Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20abf4e631d75cd04cb95793424f9681"><gtr:id>20abf4e631d75cd04cb95793424f9681</gtr:id><gtr:otherNames>Benson N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>JgjZhEUmzZM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32FC8CA6-F226-43AA-9C91-8FB0DCFC9C17</gtr:id><gtr:title>Abundance, distribution, mobility and oligomeric state of M2 muscarinic acetylcholine receptors in live cardiac muscle.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/434f6c9fd217a4e9f0052eca9fdfa359"><gtr:id>434f6c9fd217a4e9f0052eca9fdfa359</gtr:id><gtr:otherNames>Nenasheva TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn><gtr:outcomeId>pm_15899_29_23357106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36F040DE-1B24-46CE-94EF-68118555B4F9</gtr:id><gtr:title>Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0242969ff42ec0690b154fab4b80500f"><gtr:id>0242969ff42ec0690b154fab4b80500f</gtr:id><gtr:otherNames>Chan WY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>248FF08337B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3089C63-20AB-4883-9E6A-F7285E3B3229</gtr:id><gtr:title>Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13b0707f8cc69848ab0b409b93d1cd71"><gtr:id>13b0707f8cc69848ab0b409b93d1cd71</gtr:id><gtr:otherNames>Hern JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>VdUbwZTfcFC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFBDBC09-D6D2-4FDC-8A4F-D33406606709</gtr:id><gtr:title>Allosterism at muscarinic receptors: ligands and mechanisms.</gtr:title><gtr:parentPublicationTitle>Mini reviews in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97b222d6c4c271ea497431dcc0136798"><gtr:id>97b222d6c4c271ea497431dcc0136798</gtr:id><gtr:otherNames>Birdsall NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1389-5575</gtr:issn><gtr:outcomeId>2469C597296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD726E8B-BB00-47A9-A552-D26B84F909D0</gtr:id><gtr:title>Class A GPCR heterodimers: evidence from binding studies.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97b222d6c4c271ea497431dcc0136798"><gtr:id>97b222d6c4c271ea497431dcc0136798</gtr:id><gtr:otherNames>Birdsall NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>a2Hkk7TpWu9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117532193</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>